Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CYTK | PRESS-RELEASE | neutral | 1/10 | Cytokinetics, Incorporated announced it will report its Q2 results on August 6, 2026. | Jul 23, 2026 |
| OPK | PRESS-RELEASE | neutral | 1/10 | OPKO Health, Inc. announced it will report its Q2 2026 results on July 27, 2026. | Jul 23, 2026 |
| OKYO | PRESS-RELEASE | neutral | 2/10 | OKYO Pharma issued a press release announcing that Non-Executive Director John Brancaccio purchased 5,000 ordinary share | Jul 23, 2026 |
| INDV | PRESS-RELEASE | neutral | 1/10 | Indivior Pharmaceuticals Inc. announced it will report its Q2 2026 results on August 4, 2026. | Jul 23, 2026 |
| IXHL | PRESS-RELEASE | bullish | 6/10 | Incannex Healthcare announced that participant screening has commenced in its DReAMzz Phase 2 dose confirmation study fo | Jul 23, 2026 |
| WST | PRESS-RELEASE | bullish | 7/10 | West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating co | Jul 23, 2026 |
| SER | PRESS-RELEASE | mixed | 5/10 | Serina Therapeutics completed enrollment in Cohort 1 of its Phase 1b registrational trial for SER-252 (Parkinson's disea | Jul 23, 2026 |
| ARGX | PRESS-RELEASE | neutral | 5/10 | { "summary": "argenx reported Q2 2026 diluted EPS of $7.32, beating the $6.13 consensus by 19.4%, with product net sales | Jul 23, 2026 |
| SUPN | PRESS-RELEASE | neutral | 1/10 | Supernus Pharmaceuticals, Inc. announced it will report its Q2 2026 results on August 4, 2026. | Jul 22, 2026 |
| CHRS | PRESS-RELEASE | neutral | 1/10 | Coherus Oncology, Inc. announced it will report its Q2 2026 results on August 5, 2026. | Jul 22, 2026 |
| OKYO | PRESS-RELEASE | bullish | 4/10 | OKYO Pharma Chairman Gabriele Cerrone, through Panetta Partners Ltd, purchased 22,500 ordinary shares at $1.45 per share | Jul 22, 2026 |
| LLY | PRESS-RELEASE | neutral | 1/10 | Eli Lilly and Company announced it will host a conference call on August 5, 2026 to discuss its Q2 2026 results. | Jul 22, 2026 |
| PCRX | PRESS-RELEASE | neutral | 1/10 | Pacira BioSciences announced it will report its Q2 2026 results on August 4, 2026. | Jul 22, 2026 |
| MNPR | PRESS-RELEASE | bullish | 7/10 | Monopar Therapeutics initiated a rolling NDA submission to the FDA for ALXN1840 (tiomolibdate choline), a first-in-class | Jul 22, 2026 |
| LBRX | PRESS-RELEASE | bullish | 6/10 | LB Pharmaceuticals announced that its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia is enrolling faster than e | Jul 22, 2026 |
| RGEN | PRESS-RELEASE | bullish | 7/10 | Repligen acquires BioLife Solutions for $1.5B (64% stock, 36% cash), paying $31.00/share, a 24% premium to the 90-day VW | Jul 22, 2026 |
| GNTA | PRESS-RELEASE | neutral | 4/10 | Genenta Science (GNTA) reported FY2025 results for its 19%-owned affiliate Sòphia HT, showing 29.3% sales growth to €7.1 | Jul 22, 2026 |
| DYN | PRESS-RELEASE | bearish | 6/10 | Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gro | Jul 21, 2026 |
| ACRV | PRESS-RELEASE | neutral | 3/10 | Acrivon Therapeutics announced presentations at the AACR D3 conference highlighting preclinical and early clinical data | Jul 21, 2026 |
| TLX | PRESS-RELEASE | bullish | 5/10 | Telix announced peer-reviewed publication of ProstACT SELECT Phase 1 results in Cancers, confirming that 68Ga-PSMA-PET i | Jul 21, 2026 |
| WLK | PRESS-RELEASE | neutral | 1/10 | Westlake Corporation announced it will host a conference call on August 4, 2026 to discuss its Q2 2026 results. | Jul 21, 2026 |
| RNTX | PRESS-RELEASE | neutral | 3/10 | Rein Therapeutics announced that its Phase 2 RENEW trial for inhaled LTI-03 in IPF is now open in Germany, completing th | Jul 21, 2026 |
| HELP | PRESS-RELEASE | neutral | 5/10 | Helus Pharma completed enrollment in the APPROACH Phase 3 pivotal study of HLP003 for Major Depressive Disorder (MDD) ah | Jul 21, 2026 |
| RZLT | PRESS-RELEASE | neutral | 2/10 | Rezolute announced management participation in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. This is a | Jul 21, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics subsidiary CNSide Diagnostics signed a regional agreement with Medical Mutual covering ~1.2M members i | Jul 21, 2026 |
| TPST | PRESS-RELEASE | neutral | 5/10 | Tempest Therapeutics announced a strategic partnership with Hebei Senlang Biotechnology to develop TPST-4003, an in vivo | Jul 21, 2026 |
| JUNS | PRESS-RELEASE | bullish | 7/10 | Jupiter Neurosciences licensed exclusive U.S. rights to ALA-002, an FDA-designated Novel Chemical Entity (non-racemic MD | Jul 21, 2026 |
| JAZZ | PRESS-RELEASE | neutral | 1/10 | Jazz Pharmaceuticals plc announced it will report its Q2 results on August 3, 2026. | Jul 20, 2026 |
| IFF | PRESS-RELEASE | neutral | 3/10 | SuanNutra (IFF) filed a press release categorized as M&A. The document content was unavailable due to a 404 error, so no | Jul 20, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven by Precision Medicine growth. The company expects | Jul 20, 2026 |